YS-49 monohydrate
目录号 : GC37955
An inhibitor of platelet aggregation
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
YS-49 is an inhibitor of platelet aggregation.1 It inhibits ADP-, collagen-, or epinephrine-induced platelet aggregation in isolated human platelets (IC50s = 730, 92, and 3.4 ?M, respectively). YS-49 also inhibits platelet aggregation and production of thromboxane A2 (TXA2) induced by arachidonic acid in isolated rat platelets (IC50s = 3.3 and 32.8 ?M, respectively).2 It reduces LPS-induced contractions in isolated endothelium-denuded rat aortic strips in a concentration-dependent manner.3 YS-49 (50 mg/kg) decreases thrombus weight in a rat model of arterio-venous shunt thrombosis.1 It increases survival in a mouse model of septicemia induced by LPS when administered at doses of 10 and 20 mg/kg.3
1.Yun-Choi, H.S., Pyo, M.K., Park, K.M., et al.Antithrombotic effects of YS-49 and YS-51--1-naphthylmethyl analogs of higenamineThromb. Res.104(4)249-255(2001) 2.Pyo, M.K., Kim, J.M., Jin, J.-L., et al.Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregationThromb. Res.120(1)81-86(2007) 3.Kang, Y.J., Koo, E.B., Lee, Y.S., et al.Prevention of the expression of inducible nitric oxide synthase by a novel positive inotropic agent, YS 49, in rat vascular smooth muscle and RAW 264.7 macrophagesBr. J. Pharmacol.128(2)357-364(1999)
| Cas No. | SDF | ||
| Canonical SMILES | OC1=CC2=C(C(CC3=C4C=CC=CC4=CC=C3)NCC2)C=C1O.O.Br | ||
| 分子式 | C20H22BrNO3 | 分子量 | 404.3 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4734 mL | 12.3671 mL | 24.7341 mL |
| 5 mM | 0.4947 mL | 2.4734 mL | 4.9468 mL |
| 10 mM | 0.2473 mL | 1.2367 mL | 2.4734 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet